# A Study Comparing Two Formulations of Selpercatinib (LY3527723) in Healthy Participants

> **NCT05089019** · PHASE1 · COMPLETED · sponsor: **Loxo Oncology, Inc.** · enrollment: 224 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Selpercatinib

## Key facts

- **NCT ID:** NCT05089019
- **Lead sponsor:** Loxo Oncology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-29
- **Primary completion:** 2022-07-19
- **Final completion:** 2022-07-19
- **Target enrollment:** 224 (ACTUAL)
- **Last updated:** 2025-03-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05089019

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05089019, "A Study Comparing Two Formulations of Selpercatinib (LY3527723) in Healthy Participants". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05089019. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*